A phase 1 and randomized, placebo‐controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

(2017) Roger Stupp et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine–DNA Methyltransferase Biomarker Analyses

(2017) Timothy Cloughesy et al.   JOURNAL OF CLINICAL ONCOLOGY

Lomustine and Bevacizumab in Progressive Glioblastoma

(2017) Wolfgang Wick et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

(2017) Sith Sathornsumetee et al.   NEURO-ONCOLOGY

Therapeutic options in recurrent glioblastoma—An update

(2016) Katharina Seystahl et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

c-Met–mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma

(2016) Menggui Huang et al.   JOURNAL OF CLINICAL INVESTIGATION

Src family kinases differentially influence glioma growth and motility

(2015) Laura J. Lewis-Tuffin et al.   Molecular Oncology

Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma

(2015) Kathryn M. Field et al.   NEURO-ONCOLOGY

Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)

(2015) Andrew B. Lassman et al.   NEURO-ONCOLOGY

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012

(2015) Quinn T. Ostrom et al.   NEURO-ONCOLOGY

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

(2014) Walter Taal et al.   LANCET ONCOLOGY

Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial

(2013) E. Galanis et al.   CLINICAL CANCER RESEARCH

Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial

(2013) Mark R. Gilbert et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting Src Family Kinases Inhibits Bevacizumab-Induced Glioma Cell Invasion

(2013) Deborah Huveldt et al.   PLoS One

A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy

(2012) Søren Møller et al.   ACTA ONCOLOGICA

Bevacizumab and daily temozolomide for recurrent glioblastoma

(2011) Annick Desjardins et al.   CANCER

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

(2011) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

(2011) J. F. de Groot et al.   NEURO-ONCOLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

(2009) D A Reardon et al.   BRITISH JOURNAL OF CANCER

Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy

(2009) A. K. Lucio-Eterovic et al.   CLINICAL CANCER RESEARCH

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme

(2009) M. H. Cohen et al.   ONCOLOGIST

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY